Banji Oyelaran-Oyeyinka and Padmashree Gehl Sampath write:
Our analysis of the innovation process for biopharmaceutical research within Nigeria reveals specific obstacles at different stages of work that the institutions were engaged in, for three reasons. First, lack of facilities and financing to move the research to the concluding stages.Second, we found situations where significant research results had been collected, with evidence of possible utility of the process and product, but no demand by the end-users10.Third, failure to commercialize sometime resulting from institutional rigidity much of which relates to the ways traditional PRIs and universities are set up. There are two issues that recurred in our interviews namely, who initiate the process (the PRI[public research institutes] or a
firm/entrepreneur?); and what form of formal or informal contract guides the process? In advanced developing and highly industrialized countries, two broad types of formal contract are common, which are, academic entrepreneurship, and spin-off companies from public research or universities...[continue reading]
0 komentar:
Posting Komentar